Ascletis Pharma Inc.

Investors

Next Day Disclosure Returns - Share Buyback
2026-07-14
Next Day Disclosure Returns - Share Buyback
2026-07-08
Next Day Disclosure Returns - Share Buyback
2026-07-07
Voluntary Announcement - Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
2026-07-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026
2026-07-03
Next Day Disclosure Returns - Share Buyback
2026-06-30
Voluntary Announcement - Proposed Share Repurchase under the Repurchase Mandate
2026-06-30
Third Amended and Restated Memorandum and Articles of Association
2026-06-29
Poll Results of Annual General Meeting Held on June 29, 2026
2026-06-29
Next Day Disclosure Returns - Share Buyback
2026-06-26

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1